Comparison of treatment persistence, hospital utilization and costs among major depressive disorder geriatric patients treated with escitalopram versus other SSRI/SNRI antidepressants

Current Medical Research and Opinion

Volumn 24, Issue 10, 2008, Pages 2805-2813

  Wu, Eric ^a   Greenberg, Paul ^a   Yang, Elaine ^a   Yu, Andrew ^a   Ben Hamadi, Rym ^a   Erder, M Haim ^b  

^a ANALYSIS GROUP   (United States)

^b FOREST RESEARCH INSTITUTE   (United States)

Author keywords

Escitalopram; Geriatric; Healthcare costs; Hospitalization; Major depressive disorder; SSRI SNRI; Treatment persistence

Indexed keywords

ANTIDEPRESSANT AGENT; ESCITALOPRAM; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR;

AGED; ARTICLE; CLINICAL PROTOCOL; COST CONTROL; DATA BASE; DRUG COST; DRUG SUBSTITUTION; DRUG WITHDRAWAL; FEMALE; GERIATRIC CARE; HEALTH CARE COST; HEALTH SERVICE; HOSPITAL UTILIZATION; HUMAN; MAJOR CLINICAL STUDY; MAJOR DEPRESSION; MALE; PRESCRIPTION; TREATMENT OUTCOME;

AGED; AGED, 80 AND OVER; CITALOPRAM; COSTS AND COST ANALYSIS; DATABASES, FACTUAL; DEPRESSIVE DISORDER, MAJOR; FEMALE; GERIATRIC PSYCHIATRY; HEALTH SERVICES FOR THE AGED; HOSPITALIZATION; HUMANS; MALE; RETROSPECTIVE STUDIES; SEROTONIN UPTAKE INHIBITORS;

EID: 55549097838     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/03007990802336780     Document Type: Article

References (35)

1. Greenberg PE, Kessler RC, Birnbaum HG, et al. The economic burden of depression in the United States: how did it change between 1990 and 2000? J Clin Psychiatry 2003;64:1465-75
2. Greenberg PE, Stiglin LE, Finkelstein SN, et al. The economic burden of depression in 1990. J Clin Psychiatry 1993;54:405-18
3. Bradvik L, Mattisson C, Bogren M, et al. Long-term suicide risk of depression in the Lundby cohort 1947-1997 - severity and gender. Acta Psychiatr Scand 2008;117:185-91
4. National Institute of Mental Health: Depressions. At: http://www.nimh.nih.gov/publicat/depression.cfm#ptdep1
5. Mental Health: A Report from the Surgeon General. At: http://www.surgeongeneral.gov/library/mentalhealth/home.html
6. Mulsant BH, Ganguli M. Epidemiology and diagnosis of depression in late life. J Clin Psychiatry 1999;60(Suppl 20)9-15
7. Barry KL, Fleming MF, Manwell LB, et al. Prevalence of and factors associated with current and lifetime depression in older adult primary care patients. Fam Med 1998;30:366-71
8. Lyness JM, Caine ED, King DA, et al. Psychiatric disorders in older primary care patients. J Gen Intern Med 1999;14:249-54
9. Bartels SJ, Horn S, Sharkey P, Levine K. Treatment of depression in older primary care patients in health maintenance organizations. Int J Psychiatry Med 1997;27:215-31
10. Glasser M, Gravdal JA. Assessment and treatment of geriatric depression in primary care settings. Arch Fam Med 1997;6:433-8
11. Schwenk TL. Diagnosis of late life depression: the view from primary care. Biol Psychiatry 2002;52:157-63
12. Volkers AC, Nuyen J, Verhaak PF, et al. The problem of diagnosing major depression in geriatric primary care patients. J Affect Disord 2004;82:259-63
13. Krishnan KR. Biological risk factors in late life depression. Biol Psychiatry 2002;52:185-92
14. Wells KB, Stewart A, Hays RD, et al. The functioning and well-being of depressed patients. Results from the Medical Outcomes Study. JAMA 1989;262:914-19
15. Devanand DP. Comorbid psychiatric disorders in late life depression. Biol Psychiatry 2002;52:236-42
16. Penninx BW, Geerlings SW, Deeg DJ, et al. Minor and major depression and the risk of death in older persons. Arch Gen Psychiatry 1999;56:889-95
17. Katon WJ, Lin E, Russo J, et al. Increased medical costs of a population-based sample of depressed geriatric patients. Arch Gen Psychiatry 2003;60:897-903
18. Unutzer J, Patrick DL, Simon G, et al. Depressive symptoms and the cost of health services in HMO patients aged 65 years and older. A 4-year prospective study. JAMA 1997;277:1618-23
19. Luber MP, Meyers BS, Williams-Russo PG, et al. Depression and service utilization in geriatric primary care patients. Am J Geriatr Psychiatry 2001;9:169-76
20. Scolnick EM. Discovery and development of antidepressants: a perspective from a pharmaceutical discovery company. Biol Psychiatry 2002;52:154-6
21. Baldwin DS, Reines EH, Guiton C, et al. Escitalopram therapy for major depression and anxiety disorders. Ann Pharmacother 2007;41:1583-92
22. Burke WJ. Escitalopram. Expert Opin Investig Drugs 2002; 11:1477-86
23. Kennedy SH, Andersen HF, Lam RW. Efficacy of escitalopram in the treatment of major depressive disorder compared with conventional selective serotonin reuptake inhibitors and venlafaxine XR: a meta-analysis. J Psychiatry Neurosci 2006;31:122-31
24. Rao N. The clinical pharmacokinetics of escitalopram. Clin Pharmacokinet 2007;46:281-90
25. Bose A, Li D, Gandhi C. Escitalopram in the acute treatment of depressed patients aged 60 years or older. Am J Geriatr Psychiatry 2008;16:14-20
26. Kasper S, de Swart H, Friis Andersen H. Escitalopram in the treatment of depressed geriatric patients. Am J Geriatr Psychiatry 2005;13:884-91
27. Gorwood P, Weiller E, Lemming O, et al. Escitalopram prevents relapse in older patients with major depressive disorder. Am J Geriatr Psychiatry 2007;15:581-93
28. Llorca PM, Fernandez JL. Escitalopram in the treatment of major depressive disorder: clinical efficacy, tolerability and cost-effectiveness vs. venlafaxine extended-release formulation. Int J Clin Pract 2007;61:702-10
29. Murdoch D, Keam SJ. Spotlight on escitalopram in the management of major depressive disorder. CNS Drugs 2006;20:167-70
30. Wu E, Greenberg P, Yang E, et al. Comparison of escitalopram versus citalopram for the treatment of major depressive disorder in a geriatric population. Curr Med Res Opin. 2008;24:2587-95
31. Antidepressant medication management. The state of health care quality, National Committee for Quality Assurance, Washington, DC, 2006:19
32. Demyttenaere K, Hemels ME, Hudry J, et al. A cost-effectiveness model of escitalopram, citalopram, and venlafaxine as first-line treatment for major depressive disorder in Belgium. Clin Ther 2005;27:111-24
33. Sullivan PW, Valuck R, Saseen J, et al. A comparison of the direct costs and cost effectiveness of serotonin reuptake inhibitors and associated adverse drug reactions. CNS Drugs 2004; 18:911-32
34. Fernandez JL, Montgomery S, Francois C. Evaluation of the cost effectiveness of escitalopram versus venlafaxine XR in major depressive disorder. Pharmacoeconomics 2005;23:155-67
35. Croorn KF, Plosker GL. Spotlight on the pharmacoeconomics of escitalopram in depression. CNS Drugs 2004;18:469-73